VTGNVistaGen Therapeutics Inc
VTGN
VistaGen Therapeutics Inc18,084
Mkt Cap
$25.24MVolume
262,779.0052W High
$5.1452W Low
$0.43PE Ratio
-0.40VTGN Fundamentals
Price
$0.6571Prev Close
$0.6371Open
$0.645950D MA
$0.6041Beta
1.96Avg. Volume
918,120.26EPS (Annual)
-$1.67P/B
0.50Rev/Employee
$8,526.32$1.78
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of -41.18% and -8.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates
Compugen (CGEN) delivered earnings and revenue surprises of -9.14% and -16.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
Vistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called...
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product...
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product...
Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop
Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop Vistagen Therapeutics, Inc...
Vistagen Receives FDA Study May Proceed Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced receipt of a Study May Proceed letter from the U.S. Food and...
CLASS ACTION DEADLINE TONIGHT MONDAY, MARCH 16: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline Tonight
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Vistagen Therapeutics, Inc. (Vistagen or the Company) (NASDAQ: VTGN) and reminds investors of...
VTGN Deadline: VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit
VTGN Deadline: VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit VTGN Deadline: VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc...
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities...
<
1
2
...
>
Compact View
Not available
Not available